Annexon Biosciences
Brisbane, CA, United States
Yaisa Andrews Zwilling is currently Vice President, Program Team Lead at Annexon Biosciences, where she works to develop disease-modifying therapeutics for patients suffering from neurological, ophthalmic and autoimmune disorders such as Huntington’s disease, Geographic Atrophy and Lupus Nephritis by targeting complement-mediated neurodegeneration.
Originally from Trinidad-Tobago, Andrews-Zwilling completed her bachelor’s in science in biochemistry and chemistry at the University of the West Indies. She went on to train at the Max Planck Institute for Experimental Medicine in Gottingen, Germany, where she received both her master’s and PhD in neuroscience.
Andrews-Zwilling then completed her postdoctoral training at Gladstone Institutes and UC San Francisco, where she focused on apoE4, the strongest genetic factor involved in Alzheimer’s disease.
She is the recipient of many awards including: Outstanding Young Scientist Award from the Lindau Nobel Laureate Group, Germany; the Award for Young Scientists from the Alzheimer’s Association; and the National Award for Excellence in Science from the Ministry of Science and Technology and the Caribbean Academy of Sciences.
Tuesday, November 14, 2023
9:00 AM – 11:00 AM PT
Disclosure information not submitted.
